Boost for António Campinos as he ends the first year of his presidency; and good news, too, for USPTO head Andrei Iancu
The world’s largest life sciences company demonstrates that it is still a major presence in the M&A landscape, despite its stated focus on organic growth.
In an interview with IAM Rembrandts in the Attic author Kevin Rivette made the case for applicants spending a lot more on the prosecution process. We asked the market whether it agreed.
Section 101 hearings end with Senator Tillis admitting that work needs to be done on key parts of the proposal; says to expect draft legislation after 4th July break
In Return Mail SCOTUS rules that government cannot bring post issuance patent challenges; lawyers for University of Minnesota claim that decision supports their case currently before the CAFC
Transfer of microfluidics tech comes as San Diego-based Illumina faces a fierce IP fight with an upstart Chinese rival
Trailing behind the Swiss giant are DowDuPont and Bayer, both of which have seen a drop in the value of their holdings
Food and drug authorities will take responsibility for criminal IP investigations, as government re-shuffle continues. It’s good news for pharma IP owners – others may have questions
All the key takeaways from six panels and 30 witnesses across two days of hearings which highlighted the progress made and big challenges ahead as US senators put the focus on section 101
The Patent Office has proposed simplifications to Form 27, which plays a role in compulsory licensing and injunctions, after complaints by Ericsson, Nokia, Huawei and others
Patent owners will not be required to take assets off the market after making submissions; this year's programme also features new sector focus areas
Transformative agreement shows why niche investment model may appeal to cash-strapped life sciences innovators
Shenzhen BGI was once the biggest purchaser of Illumina’s gene sequencing machines. Now the two are on opposite sides of an expanding patent battle
Our week-long series on the US-China trade dispute concludes, as deal-makers working on the ground say licence transactions and tech transfer are still happening, but big uncertainties remain
Proposals seen as way of limiting overly broad grants while also reducing 101’s impact; legislators tee-up series of marathon public hearings for the summer